Replies to post #182121 on Biotech Values

[DewDiligence]

what if Gilead had experimented with RBV or dosing strengths or treatment durations in genotype 2 or 3? Oh wait; they have and they are currently doing so, and they probably will continue to do so in optimizing efficacy/safety/duration in drug treatments.

True for GT3, which is turning out to be the hardest genotype to treat for many all-oral regimens. On the other hand, GILD seems to have GT2 well covered already.